InDex Pharmaceuticals Holding AB, which is developing oncology products using DNA based sequences that modulate the immune system, has hired Johan Giléus as its chief financial officer, effective 1 May. Mr Giléus previously worked for InDex as a consultant and advised the Swedish company on its initial public offering of shares in 2016. Earlier, he was a partner and director of Deloitte Sweden. The Swedish company’s current CFO, Per-Olof Gunnesson, will continue with the company as a consultant for contractual issues.
InDex Pharmaceuticals announced the appointment on 8 March 2017.
Copyright 2017 Evernow Publishing Ltd